MAP2K7 and familial pancreatic carcinoma: Preclinical evaluations of combining a PI3K/AKT inhibitor and a MEK inhibitor in pancreatic cancer are emerging [19], and our study confirms that a synergistic effect occurs when blocking these two pathways.